MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Open accessAbstract
We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antibody titers in 4 of 6 patients who had mild illness were undetectable even though most had evidence of pneumonia. This finding implies that MERS-CoV seroepidemiologic studies markedly underestimate the extent of mild and asymptomatic infection. Obtaining convalescent-phase plasma with high antibody titers to treat MERS will be challenging.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Natural history studies suggest that SARS-CoV and MERS-CoV infections, particularly mild illnesses, may not generate long-lived antibody responses.
“This longitudinal assessment is relevant given that natural history studies suggest that SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus) infections, particularly mild illnesses, may not generate long-lived antibody responses.20-22”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P. R., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K., Convalescent Plasma Study Group, Nguyen‐Van‐Tam, J. S., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 985 · see citing works
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598 · see citing works
Corman, V. M., Albarrak, A. M., Omrani, A. S., Albarrak, M. M., Farah, M. E., Almasri, M. M., Muth, D., Sieberg, A., Meyer, B., Assiri, A. M., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ951 · Cited by 370 · see citing works
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367 · see citing works
Perera, R. A. P. M., Wang, P., Gomaa, M. R., El‐Shesheny, R., Kandeil, A., Bagato, O., Siu, L. Y.-L., Shehata, M., Kayed, A. E., Moatasim, Y., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.36.20574 · Cited by 323 · see citing works
Self-citationMiddle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015
Prevention, K. C. F. D. C. A. (2015) · Osong Public Health and Research Perspectives · doi:10.1016/j.phrp.2015.08.006 · Cited by 259 · see citing works
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T. C., Raviprakash, K. S., Balkhy, H. H., Johani, S. A., Al‐Dawood, A., Al-Qahtani, S. M., Al‐Omari, A., Al-Hameed, F. M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2209.151164 · Cited by 244 · see citing works
Viral Load Kinetics of MERS Coronavirus Infection
Oh, M., Park, W. B., Choe, P. G., Choi, S., Kim, J., Chae, J., Park, S. S., Kim, E.-C., Oh, H. S., Kim, E. J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1511695 · Cited by 224 · see citing works
Self-citationArabi, Y. M., Balkhy, H. H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al‐Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-1490-9 · Cited by 202 · see citing works
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Nsour, M. A., Alsanouri, T., Ali, S. S., Harcourt, J. L., Miao, C., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2210.160706 · Cited by 201 · see citing works
Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
Reusken, C. B. E. M., Messadi, L., Feyisa, A. D., Ularamu, H. G., Godeke, G.-J., Danmarwa, A., Dawo, F., Jemli, M. H., Melaku, S. K., Shamaki, D., et al. (2014) · Emerging infectious diseases · doi:10.3201/eid2008.140590 · Cited by 193 · see citing works
Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection
Kim, E. S., Choe, P. G., Park, W. B., Oh, H. S., Kim, E. J., Nam, E. Y., Na, S. H., Kim, M., Song, K., Bang, J. H., et al. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.11.1717 · Cited by 193 · see citing works
Self-citationKinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea
Park, W. B., Perera, R. A. P. M., Choe, P. G., Lau, E. H. Y., Choi, S. J., Chun, J. Y., Oh, H. S., Song, K., Bang, J. H., Kim, E. S., et al. (2015) · Emerging infectious diseases · doi:10.3201/eid2112.151421 · Cited by 150 · see citing works
Self-citationAntibody Response and Disease Severity in Healthcare Worker MERS Survivors
Alshukairi, A. N., Khalid, I., Ahmed, W., Dada, A. M., Bayumi, D. T., Malic, L. S., Althawadi, S., Ignacio, K. H., Alsalmi, H., Al-Abdely, H. M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2206.160010 · Cited by 139 · see citing works
Hemida, M. G., Perera, R. A. P. M., Jassim, R. A. M. A., Kayali, G., Siu, L. Y.-L., Wang, P., Chu, K. W., Perlman, S. M., Ali, M. A., Alnaeem, A. A., et al. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.23.20828 · Cited by 113 · see citing works
Self-citationSerologic Evidence for MERS-CoV Infection in Dromedary Camels, Punjab, Pakistan, 2012–2015
Saqib, M., Sieberg, A., Hussain, M. H., Mansoor, M. K., Zohaib, A., Lattwein, E., Müller, M. A., Drosten, C., & Corman, V. M. (2017) · Emerging infectious diseases · doi:10.3201/eid2303.161285 · Cited by 56 · see citing works
Muth, D., Corman, V. M., Meyer, B., Assiri, A. M., Almasri, M. M., Farah, M. E., Steinhagen, K., Lattwein, E., Al‐Tawfiq, J. A., Albarrak, A. M., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.01368-15 · Cited by 53 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595 · see citing works
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686 · see citing works
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · see citing works
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · see citing works
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504 · see citing works
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120 · see citing works
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868 · see citing works
Infection of dogs with SARS-CoV-2
Sit, T. H. C., Brackman, C. J., Ip, S. M., Tam, K. W. S., Law, P. Y.-T., To, E. M. W., Yu, V. Y. T., Sims, L. D., Tsang, D. N. C., Chu, D. K. W., et al. (2020) · Nature · doi:10.1038/s41586-020-2334-5 · Cited by 771 · see citing works
Self-citationHuang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026 · see citing works
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586 · see citing works
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572 · see citing works
Marca, A. L., Capuzzo, M., Paglia, T., Roli, L., Trenti, T., & Nelson, S. M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.06.001 · Cited by 386 · see citing works
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361 · see citing works
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M. A., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E. J., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 337 · see citing works
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352 · see citing works
Self-citationKellam, P., & Barclay, W. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001439 · Cited by 351 · see citing works
Dispinseri, S., Secchi, M., Pirillo, M. F., Tolazzi, M., Borghi, M., Brigatti, C., Angelis, M. L. D., Baratella, M., Bazzigaluppi, E., Venturi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22958-8 · Cited by 334 · see citing works
Neutralizing antibody titres in SARS-CoV-2 infections
Lau, E., Tsang, O., Hui, D. S. C., Kwan, M., Chan, W.-H., Chiu, S., Ko, R. L. W., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20247-4 · Cited by 320 · see citing works
Self-citationSerological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
Perera, R. A. P. M., Mok, C. K. P., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W.-S., Chan, J. M., Chik, T. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.16.2000421 · Cited by 322 · see citing works
Self-citationModjarrad, K., Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K. M., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30266-x · Cited by 308 · see citing works
Self-citationORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
Hachim, A., Kavian, N., Cohen, C. A., Chin, A. W. H., Chu, D. K. W., Mok, C. K. P., Tsang, O. T., Yeung, Y. C., Perera, R. A. P. M., Poon, L. L. M., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0773-7 · Cited by 262 · see citing works
Self-citationCrawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265 · see citing works
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261 · see citing works
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control
Lee, C. Y., Lin, R. T. P., Rénia, L., & Ng, L. F. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00879 · Cited by 256 · see citing works
Fenwick, C. W., Croxatto, A., Coste, A. T., Pojer, F., André, C., Pellaton, C., Farina, A., Campos, J., Hacker, D. L., Lau, K., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01828-20 · Cited by 218 · see citing works
What policy makers need to know about COVID-19 protective immunity
Altmann, D. M., Douek, D. C., & Boyton, R. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30985-5 · Cited by 223 · see citing works
Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea
Oh, M., Park, W. B., Park, S., Choe, P. G., Bang, J. H., Song, K., Kim, E. S., Kim, H. B., & Kim, N. J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.031 · Cited by 215 · see citing works
Self-citationThree-Month Follow-Up Study of Survivors of Coronavirus Disease 2019 after Discharge
Liang, L., Yang, B., Jiang, N., Fu, W., He, X., Zhou, Y., Ma, W., & Wang, X. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e418 · Cited by 213 · see citing works
Lynch, K. L., Whitman, J. D., Lacanienta, N. P., Beckerdite, E. W., Kastner, S. A., Shy, B. R., Goldgof, G. M., Levine, A. G., Bapat, S. P., Stramer, S. L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa979 · Cited by 211 · see citing works
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Townsend, J. P., Hassler, H. B., Wang, Z., Miura, S., Singh, J., Kumar, S., Ruddle, N. H., Galvani, A. P., & Dornburg, A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00219-6 · Cited by 188 · see citing works
Batawi, S., Tarazan, N., Al-Raddadi, R. M., Qasim, E. A., Sindi, A., Johni, S. A., Al-Hameed, F. M., Arabi, Y. M., Uyeki, T. M., & Alraddadi, B. M. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1165-2 · Cited by 162 · see citing works
Emergence of a novel human coronavirus threatening human health
Poon, L. L. M., & Peiris, M. J. S. (2020) · Nature Medicine · doi:10.1038/s41591-020-0796-5 · Cited by 158 · see citing works
Self-citationCowling, B. J., & Leung, G. M. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.6.2000110 · Cited by 156 · see citing works
Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection
Files, J. K., Boppana, S., Perez, M. D., Sarkar, S., Lowman, K. E., Qin, K., Sterrett, S., Carlin, E., Bansal, A., Sabbaj, S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140491 · Cited by 155 · see citing works
Kleine‐Weber, H., Elzayat, M. T., Wang, L., Graham, B. S., Müller, M. A., Drosten, C., Pöhlmann, S., & Hoffmann, M. (2018) · Journal of Virology · doi:10.1128/jvi.01381-18 · Cited by 143 · see citing works
Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
Wang, Z., Yang, X., Zhong, J., Zhou, Y., Tang, Z., Zhou, H., He, J., Mei, X., Tang, Y., Lin, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22036-z · Cited by 127 · see citing works
Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Nguyen, A. A., Habiballah, S. B., Platt, C. D., Geha, R. S., Chou, J. S., & McDonald, D. R. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108459 · Cited by 126 · see citing works
Bradley, B. T., & Bryan, A. B. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.04.006 · Cited by 124 · see citing works
Convalescent Plasma Therapy for COVID-19: State of the Art
Focosi, D., Anderson, A. O., Tang, J. W.-T., & Tuccori, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-20 · Cited by 123 · see citing works
Rosado, J., Pelleau, S., Cockram, C. A., Merkling, S. H., Nekkab, N., Demeret, C., Meola, A., Kernéis, S., Terrier, B., Fafi‐Kremer, S., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30197-x · Cited by 122 · see citing works
Reinfection With SARS-CoV-2: Implications for Vaccines
Cohen, J. I., & Burbelo, P. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1866 · Cited by 109 · see citing works
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 109 · see citing works
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Fafi-Kremer, S., Bruel, T., Madec, Y., Grant, R., Tondeur, L., Grzelak, L., Staropoli, I., Anna, F., Souque, P., Fernandes-Pellerin, S., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102915 · Cited by 108 · see citing works
Rational Vaccine Design in the Time of COVID-19
Burton, D., & Walker, L. (2020) · Cell Host and Microbe · doi:10.1016/j.chom.2020.04.022 · Cited by 112 · see citing works
Al‐Tawfiq, J. A., & Gautret, P. (2018) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2018.12.003 · Cited by 99 · see citing works
MERS-CoV as an emerging respiratory illness: A review of prevention methods
Baharoon, S. A., & Memish, Z. A. (2019) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2019.101520 · Cited by 99 · see citing works
Channappanavar, R., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144115 · Cited by 92 · see citing works
The 2020 race towards SARS-CoV-2 specific vaccines
Karpiński, T. M. M., Ożarowski, M., Seremak‐Mrozikiewicz, A., Wolski, H., & Włodkowic, D. (2020) · Theranostics · doi:10.7150/thno.53691 · Cited by 92 · see citing works
Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays
Tehrani, Z. R., Saadat, S., Saleh, E., Ouyang, X., Constantine, N. T., DeVico, A. L., Harris, A. D., Lewis, G. K., Kottilil, S., & Sajadi, M. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237828 · Cited by 87 · see citing works
Follow-up study on COVID-19 survivors one year after discharge from hospital
Zhao, Y., Yang, C., An, X., Xiong, Y., Shang, Y., He, J., Qiu, Y., Zhang, N., Huang, L., Jia, J., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.017 · Cited by 89 · see citing works
Houser, K. V., Broadbent, A., Gretebeck, L., Vogel, L., Lamirande, E. W., Sutton, T. C., Bock, K. W., Minai, M., Orandle, M. S., Moore, I. N., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006565 · Cited by 88 · see citing works
Immune response following infection with SARS‐CoV ‐2 and other coronaviruses: A rapid review
Murchú, É. Ó., Byrne, P., Walsh, K. A., Carty, P. G., Connolly, M. A., Gascun, C. F. D., Jordan, K., Keoghan, M., O’Brien, K. K., O’Neill, M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2162 · Cited by 84 · see citing works
Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P., & Dornburg, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204336119 · Cited by 86 · see citing works
Mok, C. K. P., Zhu, A., Zhao, J., Lau, E. H. Y., Wang, J., Chen, Z., Zhuang, Z., Wang, Y., Alshukairi, A. N., Baharoon, S. A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30599-5 · Cited by 85 · see citing works
Self-citationImmunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
Venditto, V. J., Haydar, D., Abdel‐Latif, A., Gensel, J. C., Anstead, M., Pitts, M. G., Creameans, J. W., Kopper, T. J., Peng, C., & Feola, D. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.574425 · Cited by 86 · see citing works
Kim, S. I., Noh, J., Kim, S., Choi, Y., Yoo, D. K., Lee, Y., Lee, H., Jung, J., Kang, C. K., Song, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6990 · Cited by 74 · see citing works
Self-citationJiang, X.-L., Wang, G.-L., Zhao, X.-N., Yan, F.-H., Yao, L., Kou, Z., Ji, S., Zhang, X.-L., Li, C., Duan, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21155-x · Cited by 78 · see citing works
Al-Abdely, H. M., Midgley, C. M., Alkhamis, A. M., Abedi, G. R., Lu, X., Binder, A. M., Alanazi, K. H., Tamin, A., Banjar, W. M., Lester, S. N., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2504.181595 · Cited by 81 · see citing works
Hui, D. S. C. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2371ed · Cited by 81 · see citing works
Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity
Ko, J., Müller, M. A., Seok, H., Park, G. E., Lee, J. Y., Cho, S. Y., Ha, Y. E., Baek, J. Y., Ys, K., Kang, J., et al. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.07.006 · Cited by 77 · see citing works
Okba, N. M. A., Raj, V. S., Widjaja, I., GeurtsvanKessel, C. H., de Bruin, E., Chandler, F. D., Park, W. B., Kim, N. J., Farag, E., Al-Hajri, M., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2510.190051 · Cited by 79 · see citing works
Self-citationVogelzang, E. H., Loeff, F. C., Derksen, N. I. L., Kruithof, S., Heer, P. O., van Mierlo, G. J., Linty, F., Mok, J. Y., van Esch, W. J. E., de Bruin, S., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000767 · Cited by 76 · see citing works
Ethical Implementation of Immunity Passports During the COVID-19 Pandemic
Voo, T. C., Clapham, H., & Tam, C. C. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa352 · Cited by 78 · see citing works
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
Wooding, D. J., & Bach, H. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.005 · Cited by 78 · see citing works
McKimm‐Breschkin, J. L., Jiang, S., Hui, D. S. C., Beigel, J. H., Govorkova, E. A., & Lee, N. L. S. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.013 · Cited by 76 · see citing works
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21037-2 · Cited by 76 · see citing works
Chukwudozie, O. S., Gray, C. M., Fagbayi, T., Chukwuanukwu, R. C., Oyebanji, V. O., Bankole, T., Adewole, A. R., & Daniel, E. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248061 · Cited by 74 · see citing works
Arthur Charpentier, A., Élie, R., Laurière, M., & Tran, V. C. (2020) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2020045 · Cited by 73 · see citing works
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 65 · see citing works
Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 64 · see citing works
Caeseele, P. V., Bailey, D., Forgie, S. E. D., Dingle, T., & Krajden, M. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.201588 · Cited by 58 · see citing works
Pagani, G., Conti, F., Giacomelli, A., Bernacchia, D., Rondanin, R., Prina, A., Scolari, V. F., Gandolfi, C. E., Castaldi, S., Marano, G., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.021 · Cited by 64 · see citing works
Dawson, P., Malik, M. R., Parvez, F., & Morse, S. S. (2019) · Vector-Borne and Zoonotic Diseases · doi:10.1089/vbz.2017.2191 · Cited by 59 · see citing works
Pelleau, S., Woudenberg, T., Rosado, J., Donnadieu, F., García, L., Obadia, T., Gardais, S., Elgharbawy, Y., Velay, A., Gonzalez, M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab375 · Cited by 58 · see citing works
Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
Kim, Y.-I., Kim, S.-M., Park, S.-J., Kim, E.-H., Yu, K.-M., Chang, J.-H., Kim, E. J., Casel, M. A. B., Rollon, R., Jang, S.-G., et al. (2021) · Emerging Microbes and Infections · doi:10.1080/22221751.2021.1872352 · Cited by 64 · see citing works
Self-citationDisappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery
Liu, A., Wang, W., Zhao, X., Zhou, X., Yang, D., Lu, M., & Lv, Y. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.009 · Cited by 59 · see citing works
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
Hasan, A., Al‐Ozairi, E., Albaqsumi, Z., Ahmad, R., & Al‐Mulla, F. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s280706 · Cited by 56 · see citing works
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
Jeewandara, C., Jayathilaka, D., Gomes, L., Wijewickrama, A., Narangoda, E., Idampitiya, D., Guruge, D., Wijayamuni, R., Manilgama, S. R., Ogg, G. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81629-2 · Cited by 55 · see citing works
Moubarak, M., Kasozi, K. I., Hetta, . F., Shaheen, H. M., Rauf, A., Al-Kuraishy, H. M., Qusti, S. Y., Alshammari, E. M., Ayikobua, E. T., Ssempijja, F., et al. (2021) · Life · doi:10.3390/life11080734 · Cited by 55 · see citing works
Gutiérrez‐Bautista, J. F., Rodríguez-Nicolás, A., Rosales‐Castillo, A., Jiménez, P., Garrido, F., Anderson, P. O., Ruiz‐Cabello, F., & López‐Ruz, M. Á. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596553 · Cited by 54 · see citing works
The Antibody Response to SARS-CoV-2 Infection
Hueston, L., Kok, J., Guibone, A., McDonald, D., Hone, G., Goodwin, J., Carter, I. W. J., Basile, K., Sandaradura, I., Maddocks, S., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa387 · Cited by 52 · see citing works
Experimental re-infected cats do not transmit SARS-CoV-2
Gaudreault, N., Carossino, M., Morozov, I., Trujillo, J., Meekins, D., Madden, D. W., Cool, K., Artiaga, B., McDowell, C. D., Bold, D., et al. (2021) · bioRxiv · doi:10.1080/22221751.2021.1902753 · Cited by 46 · see citing works
Immunity certification for COVID-19: ethical considerations
Voo, T. C., Reis, A. A., Thome, B. D. C., Ho, C. W.-L., Tam, C. C., Cirino, C. K., Emanuel, E., Beca, J. P., Littler, K., Smith, M. J., et al. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.20.280701 · Cited by 50 · see citing works
Zhou, Z., Hui, K. P. Y., So, R. T. Y., Lv, H., Perera, R. A. P. M., Chu, D. K. W., Gelaye, E., Oyas, H., Njagi, O. N., Abayneh, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103984118 · Cited by 49 · see citing works
Self-citationImplications of COVID‐19 for an ageing population
Holt, N. R., Neumann, F., McNeil, J. J., & Cheng, A. C. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50785 · Cited by 45 · see citing works
Humoral Response Dynamics Following Infection with SARS-CoV-2Preprint
Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H. R., et al. (2020) · medRxiv · doi:10.1101/2020.07.16.20155663 · Cited by 43 · see citing works
Interim Guidelines on Antiviral Therapy for COVID-19
Kim, S. B., Huh, K., Heo, J. Y., Joo, E., Kim, Y. J., Choi, W. S., Kim, Y., Seo, Y. B., Yoon, Y. K., Ku, N. S., et al. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.2.281 · Cited by 41 · see citing works
Tilley, K. B., Ayvazyan, V., Martinez, L. C., Nanda, N., Kawaguchi, E. S., O’Gorman, M. R. G., Conti, D. V., Gauderman, W. J., & Orman, S. V. (2020) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2020.09.001 · Cited by 40 · see citing works
SARS-CoV-2 Vaccine Development: An Overview and Perspectives
Liu, Y., Wang, K., Massoud, T., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 25 · see citing works
Younes, S. N., Al-Jighefee, H. T., Shurrab, F. M., Al‐Sadeq, D. W., Younes, N., Dargham, S. R., Al-Dewik, N. I. E., Qotba, H. A., Syed, M. A., Alnuaimi, A. S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9020245 · Cited by 40 · see citing works
Kahlout, R. A. A., Nasrallah, G. K., Farag, E., Wang, L., Lattwein, E., Müller, M. A., Zowalaty, M. E. E., Al‐Romaihi, H. E., Graham, B. S., Thani, A. A. A., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/1386740 · Cited by 37 · see citing works
Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19
Cheema, P. S., Nandi, D., & Nag, A. (2021) · Open Biology · doi:10.1098/rsob.210069 · Cited by 37 · see citing works
SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment
Khalaf, K., Papp, N., Chou, J. T.-T., Hana, D., Mackiewicz, A. A., & Kaczmarek, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570927 · Cited by 36 · see citing works
Transmissibility of MERS-CoV Infection in Closed Setting, Riyadh, Saudi Arabia, 2015
Kerkhove, M. D. V., Alaswad, S., Assiri, A. M., Perera, R. A. P. M., Peiris, M. J. S., Bushra, H. E. E., & BinSaeed, A. A. (2019) · Emerging infectious diseases · doi:10.3201/eid2510.190130 · Cited by 34 · see citing works
Self-citationDifferential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34 · see citing works
COVID-19: imbalanced cell-mediated immune response drives to immunopathology
Wang, J., Li, Q., Qiu, Y., & Lu, H. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2122579 · Cited by 36 · see citing works
Development and validation of different indirect ELISAs for MERS-CoV serological testing
Hashem, A. M., Alamri, S. S., Alsubhi, T. L., Siddiq, L. A., Hassan, A. M., Alawi, M., Alhabbab, R. Y., Hindawi, S., Mohammed, O. B., Amor, N. M. S., et al. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.01.005 · Cited by 32 · see citing works
Unresolved questions in the zoonotic transmission of MERS
Peiris, M. J. S., & Perlman, S. M. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.12.013 · Cited by 32 · see citing works
Self-citation
- Authors
- Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., Lau, E. H. Y., Poon, L. L. M., Peiris, M., & Oh, M.-D.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Oh, Myoung-don
- ORCID
- Venue
- Emerging Infectious Diseases
- Published
- 2017-07
- Volume
- 23
- Issue
- 7
- Pages
- 1079-1084
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- PMC
- PMC5512479
- OpenAlex
- W2612594162
- Cited by
- 227
- References
- 17
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 8 · 2023: 12 · 2022: 21 · 2021: 60 · 2020: 91 · 2019: 13 · 2018: 7 · 2017: 5
- FWCI
- 24.63
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Emerging infectious diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Funders
- Seoul National University
- Korea Health Industry Development Institute (HI15C3227)
- Seoul National University Hospital
- Hong Kong Government
- National Institutes of Health
- Health and Medical Research Fund
- National Institute of Allergy and Infectious Diseases (HHSN272201400003C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
- Keywords
- MERS-CoV, neutralizing antibodies, spike protein antibodies, antibody kinetics, antibody waning, seroconversion, convalescent plasma
- MeSH terms
- Antibodies, Viral, Disease Outbreaks, Enzyme-Linked Immunosorbent Assay, Follow-Up Studies, Humans, Neutralization Tests, Seroepidemiologic Studies, Coronavirus Infections, History, 21st Century, Republic of Korea, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
